Featured Research

from universities, journals, and other organizations

ID1 protein boosts lung cancer in smokers, non-smokers; Potential anti-oncogenic target

Date:
July 19, 2011
Source:
American Society for Microbiology
Summary:
Lung cancer is strongly correlated with smoking, and most lung cancer patients are current or former smokers. But it is not rare in nonsmokers. Now, a team of researchers shows that a protein called ID1 is a key player in lung cancer in both smokers and nonsmokers.

Lung cancer is strongly correlated with smoking, and most lung cancer patients are current or former smokers. But it is not rare in nonsmokers. Now, a team of researchers from the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, shows that a protein called ID1 is a key player in lung cancer in both smokers and nonsmokers. The research is published in the July issue of the journal Molecular and Cellular Biology.

The investigators were aware that while nicotine does not cause cancer, earlier studies, including their own, had suggested that it might promote growth and metastasis of cancers that had already formed. They exposed cultured cells to nicotine, after which these cells expressed increased levels of a protein called ID1.

"That protein was the first link between lung cancer in smokers and nonsmokers. In non-smokers, who are not exposed to copious nicotine, its expression is induced by a growth promoting protein called epidermal growth factor, which is known to be involved in cancers in non-smokers," says corresponding author Srikumar Chellappan.

The researchers then connected all this to another protein, Src, which was known to be altered in cancers, and in this altered form to promote tumor growth. "Our studies showed that inhibiting Src prevented the induction of ID1," says Chellappan. "Further, removing ID1 protein from cancer cells prevented their growth, as well as their ability to migrate or invade, which are the early steps of metastasis." They removed ID1 from the cancer cells through the use of small-interfering RNAs, which can be designed to block expression of particular proteins.

"Our studies thus show that ID1 might mediate the tumor promoting properties of nicotine, and also facilitate the growth of tumors in response to epidermal growth factor," says Chellappan. "These observations raise the possibility that targeting ID1 might be a viable strategy for combating lung cancer."


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Pillai, W. Rizwani, X. Li, B. Rawal, S. Nair, M. J. Schell, G. Bepler, E. Haura, D. Coppola, S. Chellappan. ID1 Facilitates the Growth and Metastasis of Non-Small Cell Lung Cancer in Response to Nicotinic Acetylcholine Receptor and Epidermal Growth Factor Receptor Signaling. Molecular and Cellular Biology, 2011; 31 (14): 3052 DOI: 10.1128/MCB.01311-10

Cite This Page:

American Society for Microbiology. "ID1 protein boosts lung cancer in smokers, non-smokers; Potential anti-oncogenic target." ScienceDaily. ScienceDaily, 19 July 2011. <www.sciencedaily.com/releases/2011/07/110718154836.htm>.
American Society for Microbiology. (2011, July 19). ID1 protein boosts lung cancer in smokers, non-smokers; Potential anti-oncogenic target. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/07/110718154836.htm
American Society for Microbiology. "ID1 protein boosts lung cancer in smokers, non-smokers; Potential anti-oncogenic target." ScienceDaily. www.sciencedaily.com/releases/2011/07/110718154836.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins